For the ranking of OS outcomes in patients with LM‐SCLC, the order from best to worst performance was as follows: anti‐PD‐1 + CT, anti‐angiogenesis + anti‐PD‐L1 + CT, anti‐PD‐L1 + CT, anti‐CTLA‐4 + anti‐PD‐L1 + CT, and CT. This evidence concerns the gene PDCD1 and small cell lung carcinoma.